Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... financial results after the NASDAQ Global Market closes on ... that day at 5:00 p.m. Eastern Time (2:00 p.m. ... for the third quarter as well as provide a ...
... 2011 At the eighth annual Indiana Life Sciences ... the founder of Bloomington-based Cook Group and one of ... M. Watanabe Life Sciences Champion of the Year award.  ... a tribute to his friend and colleague. ...
... BOSTON, Oct. 26, 2011 13 leading industry speakers will ... Electronic Trial Master Files on November 14-15, 2011 in ... educational exploration of the major shift taking place in the ... Often called the heart of a clinical ...
Cached Biology Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results 2BioCrossroads Awards Indiana Life Sciences Leaders 2BioCrossroads Awards Indiana Life Sciences Leaders 3BioCrossroads Awards Indiana Life Sciences Leaders 4
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... decrease in yield and an increase in the concentration of ... with the results of previous studies which have shown a ... seeds in high ozone, these results (to be presented at ... on 29th June 2009) could signal a significant income loss ...
... serious demands for the organism, and this is true even ... the ancestors of present marine mammals initiated their return to ... new medium. Dr. Michael Berenbrink and his colleagues at Liverpool ... delivering oxygen to the muscles during locomotion, has been modified ...
... SALT LAKE CITY, June 29, ... use computers and may let amputees control bionic limbs. But existing devices ... Utah study shows that brain signals controlling arm movements can be detected ... it. ...
Cached Biology News:Natural-born divers and the molecular traces of evolution 2Reading the brain without poking it 2Reading the brain without poking it 3Reading the brain without poking it 4Reading the brain without poking it 5
The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
... Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins ... TLC ≥ 90 % Cation traces: Ca ≤ 10 ... Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg Fe ... 5 mg/kg Mn ≤ 5 mg/kg Na ≤ 50 ...
... Biometras Tpersonal thermocycler provides maximum performance ... generation of Peltier elements, high heating and ... to short run times. With a maximum ... Tpersonal provides half the capacity of much ...
... One-Step Deparaffinization Solution is available ... is an easy-to-use reagent for dewaxing ... immunohistochemistry, in situ hybridization, or other ... paraffin removal consists of dipping the ...
Biology Products: